A review of the randomized clinical trials of adjuvant trastuzumab in human epidermal growth factor receptor (HER2)—positive breast cancer demonstrates the great benefit of this monoclonal antibody whose potential cardiotoxicity is a fascinating problem for the cardiologist 1. [...]
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً